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Objectives The study investigated the role of myocardial suppressor of cytokine signaling-3 (SOCS3), an intrinsic negative
feedback regulator of the janus kinase and signal transducer and activator of transcription (JAK-STAT) signaling
pathway, in the development of left ventricular (LV) remodeling after acute myocardial infarction (AMI).
Background LV remodeling after AMI results in poor cardiac performance leading to heart failure. Although it has been
shown that JAK-STAT–activating cytokines prevent LV remodeling after AMI in animals, little is known about the
role of SOCS3 in this process.
Methods Cardiac-specific SOCS3 knockout mice (SOCS3-CKO) were generated and subjected to AMI induced by perma-
nent ligation of the left anterior descending coronary artery.
Results Although the initial infarct size after coronary occlusion measured by triphenyltetrazolium chloride staining
was comparable between SOCS3-CKO and control mice, the infarct size 14 days after AMI was remarkably
inhibited in SOCS3-CKO, indicating that progression of LV remodeling after AMI was prevented in SOCS3-
CKO hearts. Prompt and marked up-regulations of multiple JAK-STAT–activating cytokines including leuke-
mia inhibitory factor and granulocyte colony-stimulating factor (G-CSF) were observed within the heart fol-
lowing AMI. Cardiac-specific SOCS3 deletion enhanced multiple cardioprotective signaling pathways
including STAT3, AKT, and extracellular signal-regulated kinase (ERK)-1/2, while inhibiting myocardial
apoptosis and fibrosis as well as augmenting antioxidant expression.
Conclusions Enhanced activation of cardioprotective signaling pathways by inhibiting myocardial SOCS3 expression pre-
vented LV remodeling after AMI. Our data suggest that myocardial SOCS3 may be a key molecule in the devel-
opment of LV remodeling after AMI. (J Am Coll Cardiol 2012;59:838–52) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.887Left ventricular (LV) remodeling after acute myocardial
infarction (AMI) is characterized by infarct expansion, LV
dilation, and fibrosis of viable myocardium (1–3). This
adverse LV remodeling depresses cardiac performance, con-
tributes to the development of heart failure, and is an
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February 28, 2012:838–52 SOCS3 and Post-Infarct Left Ventricular RemodelingAccordingly, it is important to elucidate the mechanisms
underlying post-infarct LV remodeling and to develop
therapeutic strategies that will effectively suppress this
adverse process (1,4).
The administration of cytokines such as granulocyte
colony-stimulating factor (G-CSF), erythropoietin, inter-
leukin (IL)-11, and leukemia inhibitory factor (LIF) was
recently demonstrated to prevent the development of LV
remodeling after AMI in animals (5–11). These cytokines
activate the janus kinase (JAK) and signal transducer and
activator of transcription (STAT) pathways, which have
protective roles in the development of LV remodeling after
AMI (12–16). Although JAK-STAT–activating cytokines
prevent LV remodeling after AMI in animals, little is
known about the role of a negative feedback regulator for
the JAK-STAT signaling pathway in this process.
Suppressor of cytokine signaling (SOCS) family proteins
were identified as cytokine-inducible intrinsic inhibitors of
cytokine signaling (17,18). We demonstrated previously
that SOCS1 and SOCS3 strongly inhibit JAK-STAT–
ediated cytokine signaling pathways as pseudosubstrates by
nteracting with JAK and inhibiting JAK activity (17–19).
OCS3 is induced by JAK-STAT–activating cytokines, includ-
ng G-CSF, erythropoietin, and LIF, and acts to inhibit their
ctions (18–20). We previously showed that the forced expres-
ion of SOCS3 inhibited cytokine-promoted cardiomyocyte
urvival in vitro and that cardiac-specific transgenic expression
f SOCS3 facilitated coxsackievirus-induced cardiac injury in
ice by inhibiting the JAK-STAT signaling pathway (20–22).
Thus, SOCS3 is a cytokine-inducible inhibitor of the JAK-
STAT pathway that promotes myocardial cell survival. There-
fore, we hypothesized that the inhibition of myocardial
SOCS3 would prevent LV remodeling after AMI. To test this
hypothesis, we generated cardiac-specific SOCS3 knockout
mice (SOCS3-CKO) using the Cre recombinase and loxP
system (23). We then induced AMI in these mice by perma-
nently ligating the left anterior descending coronary artery, and
investigated the role of myocardial SOCS3 in the development
of LV remodeling after AMI.
Methods
Generation of SOCS3-CKO. Because SOCS3-deficient
mice die during embryonic development as a result of
placental defects, the SOCS3 coding region in exon2 was
flanked by loxP sites (flox) (Fig. 1A), and we generated
SOCS3-flox mice to determine the tissue-specific roles of
SOCS3 (23,24). To investigate the role of JAK-STAT
signaling and its negative regulator SOCS3 in LV remod-
eling after AMI, SOCS3-flox mice were bred with
-myosin heavy chain–promoter-driven cardiac-specific
Cre recombinase transgenic mice (25). We confirmed that
SOCS3 protein was markedly reduced in SOCS3-CKO
hearts 6 h after intraperitoneal injection of lipopolysaccha-
ride (LPS) (20 mg/kg) (Fig. 1B).The mice used in this study
were 8- to 10-week-old males in
a Balb/c background. All experi-
mental procedures were per-
formed according to the guide-
lines for experiments in animals
established by the Kurume Uni-
versity Animal Care and Treat-
ment Committee for experi-
ments in animals.
Acute myocardial infarction
model. Acute myocardial in-
farction was produced by perma-
nent ligation of the left coronary
artery as previously described. To
measure infarct size 14 days after
AMI, the LV were cut into 3
transverse sections from apex to
base. Five-micrometer sections
were stained with Mallory-AZAN
staining. The extent of fibrosis was
measured in 3 sections and the
value was expressed as the ratio of
Mallory-AZAN–stained area to
total LV free wall (5). Evans blue
dye and triphenyltetrazolium chlo-
ride (TTC) stains were also per-
formed to measure initial infarct
size. Area at risk and infarct area
were determined by perfusion with
5% Evans blue and consequent
incubation with TTC at 3 h after
left coronary artery occlusion, as
previously described (12).
Western blot analysis. Western
blot analysis was performed as
described previously (20 –22)
with the use of antibodies raised
against tyrosine-phosphorylated
STAT3, serine-phosphorylated
STAT3, phosphorylated AKT,
phosphorylated extracellular
signal-regulated kinase (ERK)-
1/2, Bcl-xL, Bad, Bax, and cleaved caspase 3 antibodies
(New England BioLabs, Beverly, Massachusetts); SOCS3
(Immuno-Biological Laboratories, Takasaki, Japan); cyto-
chrome c (BD Pharmingen, Franklin Lakes, New Jersey);
porin (Invitrogen, Carlsbad, California); tubulin (Santa Cruz
Biotechnology, Santa Cruz, California); mitochondrial tran-
scriptional factor A (TFAM) (26); manganese superoxide
dismutase (Mn-SOD); and heme oxygenase (HO)-1 (Abcam,
Cambridge, United Kingdom).
TUNEL staining. To detect apoptosis, terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) staining was performed according to the manu-
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CKO  cardiac-specific
knockout mice
ERK  extracellular signal-
regulated kinase
flox  flanked byloxP site
G-CSF  granulocyte
colony-stimulating factor
HO  heme oxygenase
IL  interleukin
JAK  janus kinase
LIF  leukemia inhibitory
factor
LPS  lipopolysaccharide
LV  left ventricular
Mn-SOD  manganese
superoxide dismutase
PCR  polymerase chain
reaction
PGC  peroxisome
proliferator-activated
receptor-gamma
coactivator
ROS  reactive oxygen
species
RNA  ribonucleic acid
SOCS  suppressor of
cytokine signaling
STAT  signal transducer
and activator of
transcription
TFAM  mitochondrial
transcriptional factor A
TTC  triphenyltetrazolium
chloride
TUNEL  terminal
deoxynucleotidyl
transferase-mediated dUTP
nick end-labelingfacturer’s protocol (In Situ Apoptosis Detection kit; Takara
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SOCS3 and Post-Infarct Left Ventricular Remodeling February 28, 2012:838–52Figure 1 Generation of Cardiac-Specific SOCS3 Knockout Mice
(A) The wild-type suppressor of cytokine signaling-3 (SOCS3) allele was modified by inserting loxP sites flanking the coding lesion in the second exon2 (E2) of SOCS3.
The first exon (E1) and E2 are shown as boxes, and the SOCS3 coding region is indicated by the ATG and stop codons. Wild-type SOCS3, the targeted SOCS3 locus
(SOCS3-flox), and the deleted locus (SOCS3-deleted) are shown. (B) SOCS3, phospho-STAT3 (pY-STAT3), and STAT3 expression in heart and liver after lipopolysaccha-
ride (LPS) injection were examined using Western blot analysis with SOCS3, phospho-STAT3, and STAT3 antibodies, respectively. (C) Real-time PCR analyses for expres-
sion of SOCS family genes, including SOCS3, SOCS1, SOCS2, and cytokine-inducible SH2 protein (CIS) in the hearts after acute myocardial infarction (AMI). PBS 
phosphate-buffered saline; n.s.  not statistically significant. **p  0.01.
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February 28, 2012:838–52 SOCS3 and Post-Infarct Left Ventricular RemodelingBio Inc., Otsu, Japan). Digital photographs were taken at
400 magnification, and 25 random high-power fields
from each heart sample were chosen and quantified.
RNA extraction and real-time PCR. Total LV ribonu-
cleic acid (RNA) was isolated using TRIzol (Invitrogen) as
described previously (20–22), and 1 g of total RNA was
onverted into complimentary deoxyribonucleic acid. Ex-
ression profiles of common cytokines were performed with
he RT2 Profiler polymerase chain reaction (PCR) array for
urine common cytokines (SABiosciences, Frederick,
aryland), according to the manufacturer’s instructions.
olymerase chain reaction was performed with the StepOne
eal-time PCR machine (Applied Biosystems, Foster City,
alifornia). The Ct method was used to analyze the
xpression level of each gene. After PCR, the dissociation
urve for each gene was examined to exclude genes with
onspecific amplification or undetectable expression. The
xpression profile of each gene was displayed as a heat map
ade by using MeV MultiExperiment Viewer 4.1 (Insti-
ute for Genomic Research, Rockville, Maryland). Real-
ime PCR assays were also performed to assess the gene
xpression of mouse SOCS1, SOCS2, SOCS3, cytokine-
nducible SH2 protein (CIS), peroxisome proliferator-activated
eceptor-gamma coactivator 1-alpha (PGC-1), collagen 1, and
collagen 32, and GADPH with the corresponding primer pairs
(Applied Biosystems, #Mm00782550_s1 refer to SOCS1,
#Mm00850544 g1 refer to SOCS2, #Mm00545913 s1 refer to
SOCS3, #Mm01230623_g1 refer to CIS, #Mm01208835_m1
refer to PGC-1, Mm01254476_ml refer to collagen 3, and
#Mm99999915_g1 refer to GADPH, respectively) using the
StepOnePlus Real-Time PCR System (Applied Biosystems).
Echocardiogram. At 14 days after AMI, transthoracic
echocardiographic studies were performed under light an-
esthesia using a Vevo770 ultrasound machine (VisualSonics
Inc., Toronto, Ontario, Canada) equipped with a 30-MHz
probe. Mice were anesthetized with isoflurane and subjected
to echocardiography as previously described (20–22). Re-
cording was performed as described previously (20–22).
Statistical analysis. Data are expressed as mean  stan-
dard error (SE). Multiple group comparisons were per-
formed using 1-way analysis of variance followed by the
Bonferroni procedure for comparison of means (Figs. 2C,
3B, 4B, 6A, 7A, and 9A). Comparison of 2 groups was
nalyzed using 2-tailed Student’s t test. Survival analysis was
erformed using the Kaplan-Meier method, and between-
roup differences in survival were tested using the log-rank
Mantel-Cox) test; p values 0.05 were considered statis-
ically significant.
esults
asal phenotype of SOCS3-CKO. SOCS3-CKO pups
ere born in an expected Mendelian ratio and grew to
dulthood normally. We confirmed by Western blot that
OCS3 expression was induced in LPS-injected hearts of
ontrol mice. SOCS3 expression was markedly reduced in iPS-injected SOCS3-CKO hearts, and was accompanied by
nhanced STAT3 phosphorylation (Fig. 1B). We also con-
rmed using real-time PCR that SOCS3 messenger RNA
as markedly reduced in SOCS3-CKO hearts 2 days after
MI, and that the expression of other SOCS family genes
ncluding SOCS1 were not altered in controls or SOCS3-
KO hearts (Fig. 1C). Histological examination of SOCS3-
KO hearts at 16 weeks revealed no evidence of necrosis or
entricular fibrosis. Echocardiography confirmed preserved LV
unction and wall thickness in SOCS3-CKO, comparable to
ittermate controls (data not shown).
revention of post-infarct LV remodeling and mortality
n SOCS3-CKO. We first evaluated the initial infarct size
h after coronary ligation using Evans blue dye and TTC
taining. Both the area at risk and infarct size immediately
fter AMI were comparable between controls and SOCS3-
KO (Fig. 2A). We then compared the survival rate
etween controls and SOCS3-CKO. Approximately 45% of
ontrols died within 14 days after AMI (Fig. 2B). In
ontrast, all SOCS3-CKO survived up to 14 days after
MI. The increases in LV weight-to-body-weight ratio
nd lung weight-to-body-weight ratio 14 days after AMI
ere significantly attenuated in SOCS3-CKO compared
ith controls (Fig. 2C). Mallory-AZAN staining revealed
hat the infarct area of hearts 14 days after AMI was
ignificantly smaller in SOCS3-CKO than in controls (Fig. 2D).
chocardiographic assessment consistently revealed that
nterior wall thickness was greater, LV end-diastolic di-
ension was smaller, and ejection fraction was greater in
OCS3-CKO than in controls 14 days after AMI (Fig. 3).
hus, post-infarct LV remodeling and mortality were sig-
ificantly prevented in SOCS3-CKO.
nhanced activation of cardioprotective signaling pathways
n SOCS3-CKO after AMI. Next, we compared the acti-
ation of cardioprotective signaling pathways including
TAT3, STAT1, AKT, and ERK1/2 after AMI in controls
nd SOCS3-CKO using Western blot analysis. Whereas
TAT3 and STAT1 were promptly phosphorylated and
KT was phosphorylated 3 days after AMI, ERK1/2
hosphorylation was down-regulated up to 7 days after
MI in controls (Fig. 4A). Consistent with a previous
eport that cytokine-induced SOCS3 expression is STAT3-
ependent, SOCS3 induction was closely correlated with
TAT3 activation in the hearts of controls. In SOCS3-
KO hearts compared with controls, STAT3 phosphory-
ation was greater and more sustained, STAT1 phosphory-
ation was less, and phosphorylation of AKT and ERK1/2
as more rapid and greater up to 14 days after AMI (Fig. 4A).
hus, the activation of cardioprotective signaling pathways
ncluding STAT3, AKT, and ERK1/2 after AMI was
nhanced in SOCS3-CKO compared with controls. We
lso conducted immunohistochemical staining of phosphor-
lated STAT3 in the heart after AMI. The number of
hosphorylated STAT3 positive cells was significantly
reater in SOCS3-CKO hearts than that in control hearts
n both the border area and the remote area (Fig. 4B).
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SOCS3 and Post-Infarct Left Ventricular Remodeling February 28, 2012:838–52Figure 2 Decreased LV Remodeling and Mortality After AMI in SOCS3-CKO
(A) Evans blue dye and triphenyltetrazolium chloride staining of control (left) and cardiac-specific suppressor of cytokine signaling-3 knockout mice (SOCS3-CKO) (cen-
ter) hearts 3 h after acute myocardial infarction (AMI) (n  5). Left ventricular (LV) infarct size was expressed as percentage of the area at risk (AAR) in each group
(right). (B) Kaplan-Meier survival analysis of controls and SOCS3-CKO after AMI (n  10 mice for each group; *p  0.05 vs. controls). (C) LV to body weight ratio (left)
and lung to body weight ratio (right) in controls and SOCS3-CKO 14 days after AMI (n  6 to 10). **p  0.01 (Bonferroni adjusted; 2 comparisons). (D) Mallory-AZAN
staining of sham and AMI in control and SOCS3-CKO hearts 14 days after AMI (n  6 to 10). ** p  0.01 versus controls 14 days after AMI.
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February 28, 2012:838–52 SOCS3 and Post-Infarct Left Ventricular RemodelingCytokine-rich microenvironment in the heart after AMI.
To determine which cytokine activates JAK downstream
signaling pathways in the heart after AMI, we conducted
Figure 3 Prevention of LV Dilation and Dysfunction in SOCS3-C
Echocardiography was performed 14 days after sham operation or acute myocardi
diograms obtained from 4 groups. (B) Pooled data for echocardiographic measure
IVST  intraventricular septal thickness; LVEDD  left ventricular end-diastolic diamreal-time PCR analysis for cytokines on mice hearts 2 daysafter AMI. Multiple cytokines that activate the JAK-STAT
pathway and induce SOCS3 expression were highly ex-
pressed in the heart after AMI, demonstrating the presence
fter AMI
rction (AMI) (n  10 mice for each group). (A) Representative M-mode echocar-
in 4 groups of mice. **p  0.01 (Bonferroni adjusted; 2 comparisons).
ther abbreviations as in Figure 2.KO A
al infa
ments
eter; oof a cytokine-rich microenvironment in the ischemic myo-
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SOCS3 and Post-Infarct Left Ventricular Remodeling February 28, 2012:838–52Figure 4 Enhanced Activation of Cardioprotective Signaling Pathways in SOCS3-CKO Hearts After AMI
(A) Total cell lysate was prepared from the left ventricle of controls or SOCS3-CKO at the indicated times after AMI, and blotted with antibodies raised against tyrosine-
phosphorylated STAT3 (pY-STAT3), serine-phosphorylated STAT3 (pS-STAT3), phosphorylated AKT (p-AKT), phosphorylated ERK1/2 (p-ERK1/2), SOCS3, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). Bar graphs represent quantitative differences in pY-STAT3, pS-STAT3, p-AKT, p-ERK1/2, and SOCS3 expression (n  5 for
each). **p  0.01 versus controls after AMI; *p  0.05 versus controls after AMI. (B) Immunostaining of pY-STAT3 in hearts after sham operation or AMI (n  10 for
each). Representative photographs of the border and remote areas in hearts from each group. Values are expressed as the percentage of pY-STAT3 positive cells in the
hearts 6 h or 3 days after AMI. **p  0.01 (Bonferroni adjusted; 2 comparisons). Scale bar  100 m. AU  arbitrary units; other abbreviations as in Figure 2.
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February 28, 2012:838–52 SOCS3 and Post-Infarct Left Ventricular Remodelingcardium (Fig. 5). Expressions of several cytokines including
G-CSF and IL-11 were lower in SOCS3-CKO hearts than
that in controls (Fig. 5).
Inhibition of cardiomyocyte apoptosis in SOCS3-CKO
after AMI. To determine the mechanism underlying how
SOCS3 deletion in cardiomyocytes prevents the develop-
ment of LV remodeling, we first measured the number of
apoptotic cells by TUNEL staining 24 h after AMI. The
number of TUNEL-positive cells was significantly smaller
in SOCS3-CKO hearts than in controls (Fig. 6A). Western
blot analysis revealed that expression of the antiapoptotic
molecule Bcl-xL was much greater in SOCS3-CKO than in
controls. On the other hand, the expression of proapoptotic
molecules Bad and Bax was less in SOCS3-CKO than in
Figure 5 Expression of JAK-STAT–Activating Cytokines in Cont
Messenger ribonucleic acid was prepared from the left ventricle of control mice
analyses for cytokines were performed. Values normalized to glyceraldehyde 3
mice (n  5 for each group). **p  0.01 versus controls. *p  0.05 versus cont
granulocyte-macrophage colony-stimulating factor; IL  interleukin; JAK  janu
tions as in Figure 2.controls (Fig. 6B). The release of cytochrome c into the bcytosol after AMI was also smaller in SOCS3-CKO hearts
than in controls (Fig. 7A).
Increased PGC-1 and TFAM expressions in SOCS3-
KO hearts after AMI. Because PGC-1 and TFAM play
mportant roles in cardiac mitochondrial biology (26–28), we
xamined PGC-1 and TFAM expressions in infarct hearts
using real-time PCR and Western blot analysis, respectively.
We observed that PGC-1 expression after AMI was greater
n SOCS3-CKO hearts than in controls (Fig. 7B). We
bserved that TFAM expression was much greater in SOCS3-
KO hearts than in controls (Fig. 7C). Additionally, we
onducted immunohistochemical staining of TFAM in the
eart after AMI. The number of TFAM-positive cells was
ignificantly greater in SOCS3-CKO hearts than in controls,
d SOCS3-CKO Hearts After AMI
OCS3-CKO 2 days after AMI and real-time polymerase chain reaction (PCR)
hate dehydrogenase are expressed as fold change from the values of sham
T  cardiotrophin; G-CSF  granulocyte colony-stimulating factor; GM-CSF 
se; STAT  signal transducer and activator of transcription; other abbrevia-rol an
or S
-phosp
rols. C
s kinaoth in the border area and in the remote area (Fig. 7D).
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SOCS3 and Post-Infarct Left Ventricular Remodeling February 28, 2012:838–52Figure 6 Inhibition of Apoptosis in SOCS3-CKO Hearts After AMI
(A) Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining control or SOCS3-CKO hearts 24 h after sham operation or AMI (n  5 for
each group). Representative photographs of border area in hearts from each group (left). The graph shows the percentage of TUNEL-positive cells (right). **p  0.01
(Bonferroni adjusted; 2 comparisons). Scale bar  100 m. (B) Total cell lysate was prepared from the left ventricle of controls or SOCS3-CKO at the indicated times
after AMI, and blotted with antibodies raised against Bcl-xL, Bad, Bax, and cleaved caspase 3. Bar graphs represent the quantitative differences in Bcl-xL, Bad, Bax, and
cleaved caspase 3 expression (n  5 for each). **p  0.01 versus controls after AMI. *p  0.05 versus controls after AMI. AU  arbitrary units; GAPDH  glyceralde-
hyde 3-phosphate dehydrogenase; other abbreviations as in Figure 2.
847JACC Vol. 59, No. 9, 2012 Oba et al.
February 28, 2012:838–52 SOCS3 and Post-Infarct Left Ventricular RemodelingFigure 7 Increased PGC-1 and TFAM Expression in SOCS3-CKO Hearts After AMI
(A) The cytosolic and mitochondrial fractions were prepared from the left ventricles (LV) of controls or SOCS3-CKO 6 h after AMI and blotted with anticytochrome c antibody. Porin and
tubulin expression were examined as internal controls (n  5 for each). The experiments were repeated three times, yielding similar results. **p  0.01 (Bonferroni adjusted; 2 compar-
isons). (B) Messenger ribonucleic acid was prepared from the LV of controls or SOCS3-CKO 2 days after AMI, and real-time polymerase chain reaction (PCR) analysis for peroxisome
proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1) was performed. Values normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are expressed as fold
change from the values of sham mice (n  5 for each group). **p  0.01 versus controls; *p  0.05 versus controls. (C) Total cell lysate was prepared from the LV of controls or
SOCS3-CKO at the indicated times after AMI, and blotted with anti-mitochondrial transcriptional factor A (TFAM) antibody. Bar graphs represent quantitative differences in TFAM expres-
sion (n  5 for each). **p  0.01 versus controls after AMI. (D) Induction of TFAM expression in the viable border area and remote area. LV sections were costained with anti-TFAM
antibody (red) and phalloidin (green) 3 days after AMI. Scale bar  100 m. AU  arbitrary units; other abbreviations as in Figure 2.
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SOCS3 and Post-Infarct Left Ventricular Remodeling February 28, 2012:838–52Enhancement of antioxidant enzymes expression in
SOCS3-CKO hearts after AMI. It is well known that
mitochondria are major sources of reactive oxygen species
(ROS) and that ROS themselves promote mitochondria-
mediated myocardial apoptosis (28,29). Antioxidants such
as Mn-SOD and HO-1 prevent LV remodeling after AMI
(30,31). Western blot analysis revealed that expressions of
HO-1 and Mn-SOD were significantly greater in SOCS3-
CKO hearts after AMI (Fig. 8).
Decreased cardiac fibrosis in SOCS3-CKO hearts after
AMI. Cardiac fibrosis is a critical feature of post-infarct
LV remodeling. Therefore, we measured the fibrotic area in
Mallory-AZAN–stained hearts 14 days after AMI, and
conducted real-time PCR for genes that were involved in
fibrosis and related to the JAK-STAT pathway. The fibrotic
areas were smaller in SOCS3-CKO hearts than in controls
in both infarct and remote areas (Fig. 9A). Expression of
matrix metalloproteinase-9, connective tissue growth factor,
transforming growth factor 2, collagen 1, and collagen 3
as significantly lower and expression of tissue inhibitor of
atrix metalloproteinase-2 was significantly greater in
OCS3-CKO than in controls (Fig. 9B).
iscussion
n the present study, we attempted to determine the role of
OCS3, which is an intrinsic negative regulator of multiple
ytokines, within cardiomyocytes in the development of LV
emodeling after AMI. We observed that the deletion of
OCS3 in cardiomyocytes enhanced multiple survival path-
ays including STAT3, AKT, and ERK1/2; prevented
Figure 8 Increased Expression of Antioxidant Molecules in SOC
Western blot analyses for heme oxygenase-1 (HO-1) and manganese superoxide d
pared from left ventricles of controls or SOCS3-CKO at the indicated times after A
titative differences in HO-1 and MnSOD expression (n  5 for each). **p  0.01
other abbreviations as in Figure 2.yocardial apoptosis and fibrosis; enhanced the expression Jf antioxidants; and resulted in the prevention of LV
emodeling after AMI. Our findings suggest that cardiac
OCS3 may be a key molecule for the development of LV
emodeling after AMI.
We consider that the enhanced survival of SOCS3-CKO
fter AMI is due to the inhibitions of LV remodeling and
he subsequent heart failure. It is possible that the inhibi-
ions of LV remodeling and heart failure after AMI in
OCS3-CKO are due to the decreased infarct size. How-
ver, the initial infarct size 3 h after coronary occlusion was
imilar between SOCS3-CKO and controls. On the other
and, the infarct size 14 days after AMI was significantly
maller in SOCS3-CKO than in controls, indicating that
rogression of LV remodeling after AMI was inhibited in
OCS3-CKO hearts. On the basis of these results, we will
iscuss the cardioprotective mechanisms against LV remod-
ling after AMI in mice with a cardiac-specific SOCS3
eletion.
In our previous study, forced expression of SOCS3 in
entricular cardiomyocytes completely suppressed the anti-
poptotic action of cardiotrophin-1 and LIF by inhibiting
TAT3, AKT, and ERK1/2 signaling pathways (20), sug-
esting that cardiac SOCS3 may promote apoptosis under
athological conditions in which JAK-STAT signaling
athways are activated. Consistent with the previous study,
arada et al. (5) recently demonstrated that the cardiac-
pecific inhibition of STAT3 by the transgenic expression of
ominant-negative STAT3 abolished the beneficial effects
f G-CSF on LV remodeling after AMI. They proposed
hat the direct action of G-CSF on cardiomyocytes via the
KO Hearts After AMI
se (MnSOD) were performed (n  5 for each group). Total cell lysate was pre-
d blotted with anti–HO-1 and anti-MnSOD antibodies. Bar graphs represent quan-
controls after AMI; *p  0.05 versus controls after AMI. AU  arbitrary units;S3-C
ismuta
MI, an
versusAK-STAT3 signaling pathway plays a crucial role in
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(A) Mallory-AZAN staining of myocardial sections 14 days after AMI. Less fibrotic area was observed in SOCS3-CKO hearts than in controls. Quantitative analysis revealed signif-
icantly less fibrotic area in both infarct and remote areas. **p  0.01 (Bonferroni adjusted; 2 comparisons). (B) Messenger ribonucleic acid was prepared from the LV of con-
trols or SOCS3-CKO after AMI, and real-time polymerase chain reaction analyses for indicated genes were performed. Values normalized to glyceraldehyde 3-phosphate
dehydrogenase are expressed as fold change from the values of sham mice (n  5 for each group). **p  0.01 versus controls: *p  0.05 versus controls. CTGF  connec-
tive tissue growth factor; MMP  matrix metalloproteinase; TGF  transforming growth factor; TIMP  tissue inhibitor of metalloproteinase; other abbreviations as in Figure 2.
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present study, SOCS3 was not induced within a few hours
after coronary occlusion but was induced several hours after
coronary occlusion in control mice. We demonstrated that
the cardiac-specific deletion of SOCS3 prevented myocar-
dial apoptosis and LV remodeling after AMI by augment-
ing STAT3 activation. Although the initial infarct size was
comparable between SOCS3-CKO and controls, the num-
ber of apoptotic cells 24 h after coronary occlusion was
significantly less in SOCS3-CKO than in controls, suggest-
ing that myocardial apoptosis during infarct expansion after
AMI was prevented in SOCS3-CKO hearts. Taken to-
gether, our results suggest that ischemia-induced SOCS3
induction in cardiomyocytes may facilitate myocardial apo-
ptosis in infarct expansion during LV remodeling after
AMI.
Next we investigated the mechanisms underpinning at-
tenuated apoptosis in SOCS3-CKO hearts. We focused on
mitochondria of cardiomyocytes for 2 reasons. First, it has
been shown that mitochondria play an important role in the
regulation of apoptosis. Second, it is well known that the
antiapoptotic protein Bcl-xL is a STAT3 target gene, which
governs mitochondrial outer membrane permeabilization
and suppresses apoptosis (32,33). Recently, Wegrzyn et al.
(34) demonstrated a novel function of serine-phosphorylated
STAT3 in mitochondrial homeostasis. They reported that
serine-phosphorylated STAT3 was present in the mito-
chondria of primary tissues including the heart, and that the
activities of complexes I and II of the electron transport
chain were significantly decreased in STAT3-deficient cells
(34). In the present study, we have several lines of evidence
for preserved mitochondrial function in SOCS3-CKO
hearts. We have shown that the release of cytochrome c
from mitochondria to the cytosol was prevented in the heart
of SOCS3-CKO after AMI (Fig. 7). Both tyrosine-
phosphorylated STAT3 and serine-phosphorylated STAT3
were significantly enhanced in SOCS3-CKO hearts (Fig.
4A). We also observed that TFAM (an essential molecule
for the mitochondrial deoxyribonucleic acid transcription
and replication) (26,35) and PGC-1 (an important regu-
lator of mitochondrial biology in the heart) (27) were
transiently up-regulated after AMI, and their expression
was enhanced in SOCS3-CKO hearts. Taken together, the
present study may indicate that cardiac-specific deletion
of SOCS3 enhances STAT3 activation and prevents
mitochondria-mediated myocardial apoptosis.
Next we investigated the mechanism underpinning the
prevention of mitochondria-mediated myocardial apoptosis
in SOCS3-CKO hearts. In addition to the role of mito-
chondria as a source of ROS, mitochondria themselves are
damaged by ROS (28,29). ROS induce myocardial apopto-
sis, which plays an important role in the development and
progression of maladaptive LV remodeling after AMI
(28,29). Antioxidant enzymes such as Mn-SOD and HO-1
are defense mechanisms against ROS-mediated myocardial
injury. It has been shown that both Mn-SOD and HO-1 rprevent myocardial apoptosis and LV remodeling after AMI
(30,31). Mn-SOD and HO-1 are target genes of STAT3
(36,37). In the present study, we found that HO-1 expres-
sion was transiently and Mn-SOD was gradually up-
regulated after AMI in hearts from controls (Fig. 8).
Additionally, Mn-SOD and HO-1 expression are enhanced
during LV remodeling after AMI in SOCS3-CKO hearts.
Therefore, increased Mn-SOD and HO-1 expression may
have contributed to the prevention of mitochondria-
mediated myocardial apoptosis, leading to the inhibition of
LV remodeling after AMI in SOCS3-CKO (Fig. 10).
Cardiac fibrosis is a critical feature of post-infarct LV
remodeling. STAT3-activating cytokines such as IL-11,
G-CSF, and erythropoietin suppress cardiac fibrosis during
AMI (10,38,39). Cardiac-specific STAT3-deficient mice
exhibited a marked increase of cardiac fibrosis (40). In this
study, we found that cardiac fibrosis in SOCS3-CKO was
reduced compared with controls, and that the expressions of
connective tissue growth factor, matrix metalloproteinase-9,
and transforming growth factor 2, which promote cardiac
brosis, was reduced in SOCS3-CKO hearts compared with
ontrols. These results suggest that preventions of myocardial
poptosis as well as fibrosis may contribute to the inhibition of
ost-infarct LV remodeling in SOCS3-CKO.
In this study, the enhancement of STAT3 activation and
FAM expression, and the reduction of fibrotic response,
ere observed in both infarct and remote viable areas during
V remodeling after AMI. These results suggest an impor-
ant underlying mechanism by which the myocardium of
OCS3-CKO was protected from either ischemic injury
irectly or post-AMI stress throughout the myocardium.
Because we demonstrated that myocardial-specific
OCS3 deletion enhanced multiple cardioprotective signal-
ng pathways and ameliorated LV remodeling after AMI,
mall-molecule antagonist of SOCS3 or tissue-specific vec-
or delivery of SOCS3 inhibitor during LV remodeling after
MI may prove to be a clinically valuable strategy to
nhance the protective effect of JAK-STAT–activating
ytokines. Recently, the first phase II trial showed that an
ntravenous bolus of erythropoietin did not reduce infarct
ize in patients with AMI (41). We previously showed that
ytokine-induced SOCS3 confers resistance to cytokine
ction by inhibiting the JAK-STAT pathway (42,43).
herefore, the strategy of myocardial SOCS3 inhibition
ay be effective for AMI patients who are resistant to
ytokines such as erythropoietin.
We propose that myocardial SOCS3 is a key determinant
f LV remodeling after AMI, and SOCS3 may serve as a
ovel therapeutic target to prevent LV remodeling after
MI. Cardiac-specific STAT3-deficient mice exhibited a
aladaptive cardiac remodeling with aging (40). Therefore,
lthough the experiments reported here were restricted to
oung mice, the long-term effects of SOCS3 deletion
emain to be determined.
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